Barrington analyst Michael Petusky lowered the firm’s price target on Haemonetics (HAE) to $86 from $95 and keeps an Outperform rating on the shares. Concern about the vascular closure franchise “overshadowed every other aspect of this quarter’s results, which were “pretty good” in most other ways, the analyst tells investors. While sharing investor disappointment regarding VASCADE, the firm thinks a 26.5% markdown in shares “represents a material overreaction” and would buy the weakness.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics price target lowered to $70 from $90 at Mizuho
- Haemonetics Reports Q1 Fiscal 2026 Earnings
- Haemonetics downgraded to Neutral from Overweight at JPMorgan
- Haemonetics: Strong Plasma Performance and Growth in Blood Management Justify Buy Rating Despite Interventional Challenges
- Haemonetics price target lowered to $85 from $105 at BTIG